Skip to Main content Skip to Navigation
Journal articles

Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

Abstract : There is an urgent need for drugs, therapies and vaccines to be available to protect the human population against COVID-19. One of the first approaches taken in the COVID-19 global response was to consider repurposing licensed drugs. This commentary highlights an extraordinary international collaborative effort of independent researchers who have recently all come to the same conclusion—that chloroquine or hydroxchloroquine are unlikely to provide clinical benefit against COVID-19.
Complete list of metadata

Cited literature [13 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02964247
Contributor : Myriam Bodescot <>
Submitted on : Monday, October 12, 2020 - 11:57:17 AM
Last modification on : Saturday, July 3, 2021 - 12:29:06 AM
Long-term archiving on: : Wednesday, January 13, 2021 - 6:42:08 PM

File

s41467-020-17907-w.pdf
Publication funded by an institution

Identifiers

Citation

Simon Funnell, William Dowling, César Muñoz-Fontela, Pierre-Stéphane Gsell, Donald Ingber, et al.. Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients. Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.4253. ⟨10.1038/s41467-020-17907-w⟩. ⟨inserm-02964247⟩

Share

Metrics

Record views

126

Files downloads

205